300347.SZ
泰格医药
SZSE · Healthcare · M 科研服务 · CN
CNY 49.16
−9.58%Year over year
Reported trailing growth
- Revenue
- +8.7%
- EBITDA
- —
- EBIT
- +184.5%
- EPS
- +134.7%
- Free cash flow
- +19.1%
- Operating cash flow
- +7.6%
Forward estimates
Based on analyst estimates
- Revenue
- -41.4%
- EBITDA
- +13.1%
- EPS
- -7.5%
Three-year CAGR
- Revenue
- -1.2%
- EBITDA
- -22.9%
- EBIT
- -26.9%
- Net income
- -23.8%
- EPS
- -23.5%
- Free cash flow
- -0.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026